FormulaFolio Investments LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 23,032 shares of the company’s stock after acquiring an additional 1,298 shares during the period. FormulaFolio Investments LLC’s holdings in Johnson & Johnson were worth $3,429,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Lake Point Wealth Management grew its holdings in shares of Johnson & Johnson by 144.4% in the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after buying an additional 169 shares during the period. Islay Capital Management LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $42,000. FAI Wealth Management grew its holdings in shares of Johnson & Johnson by 45.9% in the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after buying an additional 101 shares during the period. SeaBridge Investment Advisors LLC grew its holdings in shares of Johnson & Johnson by 160.0% in the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after buying an additional 200 shares during the period. Finally, HWG Holdings LP acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $49,000. Institutional investors own 67.44% of the company’s stock.

A number of equities analysts recently weighed in on the stock. Citigroup upped their target price on shares of Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Credit Suisse Group upped their target price on shares of Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday. Independent Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the stock from $161.00 to $164.00 in a research note on Monday, July 20th. Bank of America reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 20th. Finally, Raymond James upped their target price on shares of Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $164.93.

Shares of JNJ stock opened at $148.10 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25. The firm’s 50-day moving average is $148.57 and its 200-day moving average is $146.59. The stock has a market cap of $389.92 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 3.36 and a beta of 0.68. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $157.00.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.98 by $0.22. The company had revenue of $21.08 billion for the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. Johnson & Johnson’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.12 EPS. Sell-side analysts predict that Johnson & Johnson will post 8 EPS for the current fiscal year.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the transaction, the executive vice president now directly owns 21,682 shares in the company, valued at $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Story: How to calculate compound interest

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.